Apolipoprotein E (
apoE) is a multifunctional plasma
glycoprotein involved in
lipoprotein metabolism and a range of cell signalling phenomena.
ApoE-deficient (
apoE(-/-)) mice exhibit severe hypercholesterolaemia and are an excellent model of human
atherosclerosis.
ApoE somatic gene transfer and
bone marrow transplantation in
apoE(-/-) mice results in reversal of hypercholesterolaemia, inhibition of
atherogenesis and regression of
atherosclerotic plaque density. Replication defective adeno-associated virus vectors (rAAVs) are an attractive system currently in clinical trial for muscle-based heterologous gene therapy to express secreted recombinant
plasma proteins. Here we have applied rAAV transduction of skeletal muscle to express wild-type (epsilon3) and a defective receptor-binding mutant (epsilon2) human
apoE transgene in
apoE(-/-) mice. In treated animals,
apoE mRNA was present in transduced muscles and, although plasma levels of recombinant
apoE fell below the detection levels of our ELISA (ie <10 ng/ml), circulating
antibodies to human
apoE and rAAV were induced. Up to 3 months after a single administration of rAAV/
apoE3, a significant reduction in
atherosclerotic plaque density in aortas of treated animals was observed (approximately 30%), indicating that low-level rAAV-mediated
apoE3 expression from skeletal muscle can retard atherosclerotic progression in this well-defined genetic model.